Patent 9506030 was granted and assigned to Regulus Therapeutics on November, 2016 by the United States Patent and Trademark Office.
Described herein are conjugated modified oligonucleotides that are complementary to a target RNA. The conjugate facilitates cellular uptake of the modified oligonucleotide, resulting improved potency.